Latest News
Cruelly high cost of drugs in U.S.
We Americans pay more for medicines than almost any other industrialized nation in the world. here are just a few shocking examples of drug company profiteering in recent years, according, in part, to a superb 16-page report and analysis by Medscape Medical News. Imatinib (brand name Gleevec) sold by Novartis to treat chronic myelogenous leukemia, cost in 2001 about $30,000 per year. Imatinib has now tripled in price, retailing for about $90,000. Gleevec has become Novartis’s best-selling drug and brought in about $4.7 billion in 2012….Read More
This posting is presented for informational purposes only and does not represent legal or financial guidance. Any opinions or interpretations presented are either those of the original author or, in the case of articles authored by the AMAC Foundation, are the opinions of AMAC Foundation staff, originally trained and accredited by the National Social Security Association (NSSA) and certified via the AMAC Foundation. Any links included in the article are valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the links’ validity. NSSA and the AMAC Foundation and its staff are not affiliated with or endorsed by the Social Security Administration or any other governmental entity. To submit a question, visit our website (https://amacfoundation.org/services/) or email us at ssadvisor@amacfoundation.org. Because we are a non-profit organization, there is no charge for these services.